Immunotherapies & Innovations for Infectious Diseases Congress 2020
December 9-10, 2020
Digital Edition
ENYO will attend the 4th edition of I4ID congress. The purpose of this two-day congress is to foster interactions between pharmaceutical industries, research labs, service providers, technology developers, and clinicians, thereby contributing to the development of innovative strategies against infectious diseases in a multidisciplinary approach.
New publication : A new class of molecule targeting the NEET family of proteins
ENYO is proud to share international collaborative study showing the development of MITO-C (one compound of EYP002 series) a new class of molecule targeting the
NEET family of protein. This work co-led by Etienne Morel (INEM, Paris, France) and Benoît de Chassey (ENYO Pharma, Lyon France) and sponsored by ENYO Pharma nicely shows that MITO-C (one compound of EYP002 series) modulates mitochondria morphogenesis and stabilizes ER-Mitochondria contact sites. This seminal fundamental results opens potential indications that go beyond infectious diseases e.g.
Vonafexor accepted as the generic name for EYP001 by the WHO
We are pleased to announce that the World Health Organization (WHO) has accepted the international non-proprietary name (INN, or generic name) vonafexor for our FXR agonist lead candidate previously referred to as EYP001.
AASLD 2020
13-16 November, 2020
Digital edition
ENYO Pharma attended the 2020 digital edition of AASLD meeting.
The meeting confirms vonafexor (EYP001, FXRag) unique positioning for HBV and possible differentiated profile for NASH with ph2s on track to deliver in H1 2021.
We also presented a poster describing a novel small molecule modulating the mitochondrial NEET proteins that improves inflammation and fibrosis in liver and kidneys of NASH mice :
American Society of Nephrology – Kidney Week 2020
ENYO Pharma is present at the digital Kidney Week 2020 organized by the ASN with a poster. ASN has been honored to host the world’s premier meeting in nephrology for 50+ years, which has been “Reimagined” as a fully digital meeting.
“A novel small molecule modulating the mitochondrial NEET proteins improves inflammation and fibrosis in kidneys of NASH mice”
Latest Press Release 